Bausch Health Companies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bausch Health Companies (BHC).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

4Hold

1Sell

Consensus RatingHold# Analysts5Avg. Consensus PT$7Upside to Avg. PT+14.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 27, 2026	RBC Capital	Douglas Miehm	PT Cut	Sector Perform	$10→$9
Feb 25, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$8→$7
Jan 7, 2026	Truist Securities	Les Sulewski	PT Raise	Hold	$7→$8
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$8
May 2, 2025	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$9→$10
Apr 7, 2025	RBC Capital	Douglas Miehm	PT Cut	Sector Perform	$9→$9
Feb 6, 2025	Jefferies	David Steinberg	Downgrade	Buy→Hold	$12→$8
Jan 30, 2025	RBC Capital	Douglas Miehm	PT Cut	Sector Perform	$11→$10
Nov 1, 2024	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$10→$11
Aug 2, 2024	RBC Capital	Douglas Miehm	PT Cut	Sector Perform	$10→$9
Aug 2, 2024	Piper Sandler	David Amsellem	Downgrade	Neutral→Underweight	$9→$3
Jul 25, 2024	Truist Securities	Gregory Fraser	PT Cut	Hold	$8→$7
Jul 10, 2024	Raymond James	Michael Freeman	Initiate	Market Perform	$8
Apr 23, 2024	RBC Capital	Douglas Miehm	PT Cut	Sector Perform	$12→$11
Apr 12, 2024	RBC Capital	Douglas Miehm	Maintained	Sector Perform	$12
Apr 5, 2024	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$9→$12
Feb 23, 2024	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$8→$9

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and lowers the price target from $10 to $9.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7

Barclays analyst Glen Santangelo maintains Bausch Health Companies (NYSE:BHC) with a Equal-Weight and lowers the price target from $8 to $7.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Bausch Health Companies, Raises Price Target to $8

Truist Securities analyst Les Sulewski maintains Bausch Health Companies (NYSE:BHC) with a Hold and raises the price target from $7 to $8.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8

Barclays analyst Glen Santangelo initiates coverage on Bausch Health Companies (NYSE:BHC) with a Equal-Weight rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10

RBC Capital analyst Douglas Miehm maintains Bausch Health Companies (NYSE:BHC) with a Sector Perform and raises the price target from $8.5 to $10.

Benzinga Newsdesk

PRO
Jefferies Downgrades Bausch Health Companies to Hold, Lowers Price Target to $8

Jefferies analyst David Steinberg downgrades Bausch Health Companies (NYSE:BHC) from Buy to Hold and lowers the price target from $12 to $8.

Benzinga Newsdesk

Bausch Health Companies Inc

Bausch Health Companies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9

PRO
Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7

PRO
Truist Securities Maintains Hold on Bausch Health Companies, Raises Price Target to $8

PRO
Barclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10

PRO
Jefferies Downgrades Bausch Health Companies to Hold, Lowers Price Target to $8

People Also Watch

People Also Watch

Bausch Health Companies Inc

Bausch Health Companies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9

PROBarclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7

PROTruist Securities Maintains Hold on Bausch Health Companies, Raises Price Target to $8

PROBarclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8

PRORBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10

PROJefferies Downgrades Bausch Health Companies to Hold, Lowers Price Target to $8

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $9

PRO
Barclays Maintains Equal-Weight on Bausch Health Companies, Lowers Price Target to $7

PRO
Truist Securities Maintains Hold on Bausch Health Companies, Raises Price Target to $8

PRO
Barclays Initiates Coverage On Bausch Health Companies with Equal-Weight Rating, Announces Price Target of $8

PRO
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $10

PRO
Jefferies Downgrades Bausch Health Companies to Hold, Lowers Price Target to $8